Summary
For Year 2026-27, Trident Texofab reports the following shareholding: Total Promoters at 32.16%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 67.84%. This breakdown provides a quick snapshot of ownership distribution for Trident Texofab in 2026-27.
Trident Texofab FAQs
As of 04-2026, the promoter shareholding in Trident Texofab stands at 32.16% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Trident Texofab is 0% and 0% respectively.
The retail shareholding of the Trident Texofab is 67.84%.
Changes in shareholding patterns of Trident Texofab can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Trident Texofab are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
